Document Detail

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
MedLine Citation:
PMID:  18757948     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Patients with diabetes mellitus (DM) are at high risk for recurrent cardiovascular events after acute coronary syndromes, in part because of increased platelet reactivity. The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) showed an overall reduction in ischemic events with more intensive antiplatelet therapy with prasugrel than with clopidogrel but with more bleeding. We compared prasugrel with clopidogrel among subjects with DM in TRITON-TIMI 38. METHODS AND RESULTS: We classified 13 608 subjects on the basis of preexisting history of DM and further according to insulin use. Prespecified analyses of the primary (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) and key secondary end points, including net clinical benefit (death, nonfatal myocardial infarction, nonfatal stroke, and nonfatal TIMI major bleeding) were compared by use of the log-rank test. We found that 3146 subjects had a preexisting history of DM, including 776 receiving insulin. The primary end point was reduced significantly with prasugrel among subjects without DM (9.2% versus 10.6%; hazard ratio [HR], 0.86; P=0.02) and with DM (12.2% versus 17.0%; HR, 0.70; P<0.001, P(interaction)=0.09). A benefit for prasugrel was observed among DM subjects on insulin (14.3% versus 22.2%; HR, 0.63; P=0.009) and those not on insulin (11.5% versus 15.3%; HR, 0.74; P=0.009). Myocardial infarction was reduced with prasugrel by 18% among subjects without DM (7.2% versus 8.7%; HR, 0.82; P=0.006) and by 40% among subjects with DM (8.2% versus 13.2%; HR, 0.60; P<0.001, P(interaction)=0.02). Although TIMI major hemorrhage was increased among subjects without DM on prasugrel (1.6% versus 2.4%; HR, 1.43; P=0.02), the rates were similar among subjects with DM for clopidogrel and prasugrel (2.6% versus 2.5%; HR, 1.06; P=0.81, P(interaction)=0.29). Net clinical benefit with prasugrel was greater for subjects with DM (14.6% versus 19.2%; HR, 0.74; P=0.001) than for subjects without DM (11.5% versus 12.3%; HR, 0.92; P=0.16, P(interaction)=0.05). CONCLUSIONS: Subjects with DM tended to have a greater reduction in ischemic events without an observed increase in TIMI major bleeding and therefore a greater net treatment benefit with prasugrel compared with clopidogrel. These data demonstrate that the more intensive oral antiplatelet therapy provided with prasugrel is of particular benefit to patients with DM.
Stephen D Wiviott; Eugene Braunwald; Dominick J Angiolillo; Simha Meisel; Anthony J Dalby; Freek W A Verheugt; Shaun G Goodman; Ramon Corbalan; Drew A Purdy; Sabina A Murphy; Carolyn H McCabe; Elliott M Antman;
Related Documents :
17160548 - Prehospital fibrinolysis with dual antiplatelet therapy in st-elevation acute myocardia...
10436138 - Low-molecular-weight heparin should replace unfractionated heparin in the management of...
11728348 - Prospective comparison of hemorrhagic complications after treatment with enoxaparin ver...
9628448 - New therapies for unstable angina and non-q-wave myocardial infarction: recent clinical...
7138898 - The effect of excess (acyl) carnitine on lipid metabolism in rat heart.
21289918 - Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-08-31
Journal Detail:
Title:  Circulation     Volume:  118     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-10-14     Completed Date:  2008-11-14     Revised Date:  2009-06-30    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1626-36     Citation Subset:  AIM; IM    
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Coronary Thrombosis / complications,  drug therapy
Diabetes Mellitus, Type 1 / complications*,  drug therapy
Diabetes Mellitus, Type 2 / complications*
Hypoglycemic Agents / administration & dosage
Insulin / administration & dosage
Kaplan-Meiers Estimate
Middle Aged
Myocardial Infarction / complications,  drug therapy*
Myocardial Ischemia / complications,  drug therapy
Piperazines / administration & dosage*
Platelet Aggregation Inhibitors / administration & dosage*
Thiophenes / administration & dosage*
Thrombolytic Therapy / methods*
Ticlopidine / administration & dosage,  analogs & derivatives
Treatment Outcome
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Thiophenes; 0/prasugrel; 11061-68-0/Insulin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel
Comment In:
Circulation. 2009 Jun 30;119(25):e601; author reply e602-3   [PMID:  19564566 ]
Circulation. 2008 Oct 14;118(16):1607-8   [PMID:  18852375 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic basis of evolutionary adaptation by Escherichia coli to stressful cycles of freezing, thawin...
Next Document:  Alignment in total knee replacement.